Gliptadin Drug Interactions

Co-administration of multiple twice-daily of metformin with sitagliptin did not meaningfully alter the pharmacokinetics of sitagliptin in patients with type 2 diabetes.
Concomitant medications did not have a clinically meaningful effect on the pharmacokinetics of sitagliptin. Medications assessed were those that are commonly administered to patients with type 2 diabetes including the following: Cholesterol lowering agents: Statins, fibrates, ezetimibe.
Anti-platelet agents: Clopidogrel.
Antihypertensives: ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, hydrochlorothiazide.
Analgesics and non-steroidal anti-inflammatory agents: Naproxen, diclofenac, celecoxib.
Anti-depressants: Bupropion, fluoxetine, sertraline.
Antihistamines: Cetirizine.
Proton-pump inhibitors: Omeprazole, lansoprazole.
Medications for erectile dysfunction: Sildenafil.
Digoxin: Increase in AUC (11%) is not considered to be clinically meaningful. Patients receiving digoxin should be monitored appropriately. No dosage adjustment of digoxin or sitagliptin is recommended.
Cyclosporine or other p-glycoprotein inhibitors: Ketoconazole, no dosage adjustment is recommended when co-administered with sitagliptin.